Visionairy Health, is a Health-tech AI company. Today they announced they obtained CE Marking for X1, its artificial intelligence (AI) based chest x-ray triage and prioritization product. X1 is a state-of-the-art medical device that uses deep learning to analyze chest x-rays, flagging those images that are suggestive of the presence of one or more of 15 pre-specified findings (including tuberculosis, pneumothorax, and lung nodules).
Visionairy Health notes it has been trained using hundreds of thousands of chest x-rays from dozens of geographical locations. X1 is PACS agnostic and can be easily integrated with existing radiology software. The software’s notifications act as a secondary check in parallel to physicians’ independent assessment to ensure that imaging studies with any prespecified findings are brought to their immediate attention.
“We’re excited to receive CE Marking, as this allows us to deploy X1 in Europe and delve into the other markets in the Middle East, Africa, and Asia as a next step,” says Moustafa Amin, Co-founder and CEO of Visionairy Health.
Visionairy Health has partnerships with large healthcare providers in those regions and they are eager to use X1. Dr. Hesham Zaki, VP of Radiology and Informatics at GNP Hospitals Group, an early partner of VH, says: “At GNP, we process a large number of chest x-rays every day, so we are looking forward to using the X1 triage tool. With X1, our physicians can be more efficient and focus on scans that require their immediate attention.”
X1 is part of a suite of AI products being developed by VH to help clinicians manage the ever-increasing volume of diagnostic radiography in hospitals and clinics around the world. The CE marking of X1 paves the way for its commercial launch in most regions of the world
